Cargando…

Emergence of Drug Resistance Is Associated with an Increased Risk of Death among Patients First Starting HAART

BACKGROUND: The impact of the emergence of drug-resistance mutations on mortality is not well characterized in antiretroviral-naïve patients first starting highly active antiretroviral therapy (HAART). Patients may be able to sustain immunologic function with resistant virus, and there is limited ev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hogg, Robert S, Bangsberg, David R, Lima, Viviane D, Alexander, Chris, Bonner, Simon, Yip, Benita, Wood, Evan, Dong, Winnie W. Y, Montaner, Julio S. G, Harrigan, P. Richard
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2006
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1569883/ https://www.ncbi.nlm.nih.gov/pubmed/16984218 http://dx.doi.org/10.1371/journal.pmed.0030356

Ejemplares similares

Aboriginal status is a prognostic factor for mortality among antiretroviral naïve HIV-positive individuals first initiating HAART
por: Lima, Viviane D, et al.
Publicado: (2006)

Expansion of HAART Coverage Is Associated with Sustained Decreases in HIV/AIDS Morbidity, Mortality and HIV Transmission: The “HIV Treatment as Prevention” Experience in a Canadian Setting
por: Montaner, Julio S.G., et al.
Publicado: (2014)

Expanding HAART Treatment to All Currently Eligible Individuals under the 2008 IAS-USA Guidelines in British Columbia, Canada
por: Lima, Viviane D., et al.
Publicado: (2010)

Development and Validation of a Composite Programmatic Assessment Tool for HIV Therapy
por: Lima, Viviane D., et al.
Publicado: (2012)

Application and Validation of Case-Finding Algorithms for Identifying Individuals with Human Immunodeficiency Virus from Administrative Data in British Columbia, Canada
por: Nosyk, Bohdan, et al.
Publicado: (2013)

Limited Evolution of Inferred HIV-1 Tropism while Viremia Is Undetectable during Standard HAART Therapy
por: Lee, Guinevere Q., et al.
Publicado: (2014)

Trends in reported AIDS defining illnesses (ADIs) among participants in a universal antiretroviral therapy program: an observational study
por: Jafari, Siavash, et al.
Publicado: (2011)

Technical and Regulatory Shortcomings of the TaqMan Version 1 HIV Viral Load Assay
por: Brumme, Chanson J., et al.
Publicado: (2012)

Clinical Features, Treatment, and Outcome of HIV-Associated Immune Thrombocytopenia in the HAART Era
por: Ambler, Kimberley L. S., et al.
Publicado: (2012)

Rates of inappropriate antiretroviral prescription among injection drug users
por: Wood, Evan, et al.
Publicado: (2007)

Disparities in the Burden of HIV/AIDS in Canada
por: Hogg, Robert S., et al.
Publicado: (2012)

Correction: Disparities in the Burden of HIV/AIDS in Canada
por: Hogg, Robert S., et al.
Publicado: (2018)

Estimated Drug Overdose Deaths Averted by North America's First Medically-Supervised Safer Injection Facility
por: Milloy, M-J. S., et al.
Publicado: (2008)

Comparing the efficacy of efavirenz and boosted lopinavir using viremia copy-years
por: Lima, Viviane D, et al.
Publicado: (2014)

Long-term effectiveness of initiating non-nucleoside reverse transcriptase inhibitor- versus ritonavir-boosted protease inhibitor-based antiretroviral therapy: implications for first-line therapy choice in resource-limited settings
por: Lima, Viviane D, et al.
Publicado: (2016)

Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function
por: Guillemi, Silvia A, et al.
Publicado: (2016)

Physician's manual reporting underestimates mortality: evidence from a population-based HIV/AIDS treatment program
por: Au-Yeung, Christopher G, et al.
Publicado: (2010)

Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study
por: Wood, Evan, et al.
Publicado: (2009)

Cost-Effectiveness of Antiretroviral Therapy for Multidrug-Resistant HIV: Past, Present, and Future
por: Harris, Marianne, et al.
Publicado: (2012)

“Dynamic Range” of Inferred Phenotypic HIV Drug Resistance Values in Clinical Practice
por: Swenson, Luke C., et al.
Publicado: (2011)

Overview of cancer incidence and mortality among people living with HIV/AIDS in British Columbia, Canada: Implications for HAART use and NADM development
por: Chiu, Connie G., et al.
Publicado: (2017)

Estimation of measurement error in plasma HIV-1 RNA assays near their limit of quantification
por: Lima, Viviane D., et al.
Publicado: (2017)

HIV/AIDS in Vancouver, British Columbia: a growing epidemic
por: McInnes, Colin W, et al.
Publicado: (2009)

Physicians’ patient base composition and mortality among people living with HIV who initiated antiretroviral therapy in a universal care setting
por: Allan, Beverly, et al.
Publicado: (2019)

The impact of HCV co-infection status on healthcare-related utilization among people living with HIV in British Columbia, Canada: a retrospective cohort study
por: Ma, Huiting, et al.
Publicado: (2018)

Nephrotoxicity of HAART
por: Kalyesubula, Robert, et al.
Publicado: (2011)

Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort
por: Di Biagio, Antonio, et al.
Publicado: (2014)

Prevalence and correlates of abscesses among a cohort of injection drug users
por: Lloyd-Smith, Elisa, et al.
Publicado: (2005)

Changes in mortality rates and causes of death in a population-based cohort of persons living with and without HIV from 1996 to 2012
por: Eyawo, Oghenowede, et al.
Publicado: (2017)

The impact of scaling-up combination antiretroviral therapy on patterns of mortality among HIV-positive persons in British Columbia, Canada
por: Lima, Viviane Dias, et al.
Publicado: (2015)

Predictors of early death in a cohort of Ethiopian patients treated with HAART
por: Jerene, Degu, et al.
Publicado: (2006)

Emergency department utilization by HIV-positive adults in the HAART era
por: Venkat, Arvind, et al.
Publicado: (2008)

Factors Impacting Early Mortality in Tuberculosis/HIV Patients: Differences between Subjects Naïve to and Previously Started on HAART
por: Schmaltz, Carolina Arana Stanis, et al.
Publicado: (2012)

Survival of HIV patients with tuberculosis started on simultaneous or deferred HAART in the THRio cohort, Rio de Janeiro, Brazil
por: Saraceni, Valeria, et al.
Publicado: (2014)

Neurodegeneration in the HAART era
por: Brew, Bruce J
Publicado: (2010)

Methodology for evaluating Insite: Canada's first medically supervised safer injection facility for injection drug users
por: Wood, Evan, et al.
Publicado: (2004)

Adherence to HAART: A Systematic Review of Developed and Developing Nation Patient-Reported Barriers and Facilitators
por: Mills, Edward J, et al.
Publicado: (2006)

Transportation Costs Impede Sustained Adherence and Access to HAART in a Clinic Population in Southwestern Uganda: A Qualitative Study
por: Tuller, David M., et al.
Publicado: (2009)

Virologic suppression and mortality of patients who migrate for HIV care in the province of British Columbia, Canada, from 2003 to 2012: a retrospective cohort study
por: Lima, Viviane Dias, et al.
Publicado: (2015)

Disability-adjusted life years associated with chronic comorbidities among people living with and without HIV: Estimating health burden in British Columbia, Canada
por: Nanditha, Ni Gusti Ayu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gsk24b0qii7mbg45qim1n1bdq7